Surveillance and Outcomes of Pediatric Hematopoietic Stem Cell Transplantation Recipients During the Recent COVID-19 Outbreak in China DOI Creative Commons
Xiaodong Wang, Uet Yu, Chao Ding

et al.

Infection and Drug Resistance, Journal Year: 2023, Volume and Issue: Volume 16, P. 7455 - 7464

Published: Dec. 1, 2023

The COVID-19 pandemic presents challenges for healthcare systems globally, especially in vulnerable populations such as pediatric hematopoietic stem cell transplant (HSCT) recipients. This study examines the clinical characteristics and outcomes of infection HSCT recipients within one year post-HSCT.Retrospective analysis was conducted on data from 247 patients. None them had received SARS-CoV-2 vaccination or prior infection. confirmed using RT-PCR testing. disease severity categorized according to established guidelines. Demographic, clinical, laboratory, imaging treatment were collected.The median age cohort 7±3.7 years, with thalassemia major predominant underlying disease. Allogeneic performed majority cases, haploidentical donors being most common source grafts. Nearly half patients developed COVID-19, significantly higher rates observed over 100 days compared post-HSCT (40.1% vs 21.7%, p<0.05, Fisher's Exact test). Fever (n=107, 43.2%) cough (n=88, 35.6%) symptoms. While mild did not require specific anti-viral treatment, a significant proportion required hospitalization (n=34, 13.8%). Various treatments employed hospitalized patients, including Paxlovid (n=19, 55.9%), methylprednisolone (n=7, 20.6%), IL-6 antibody (n=2, 5.9%), mesenchymal cells (n=3, 8.8%), exosomes nebulization therapy 5.9%). Despite multidisciplinary approaches, patient died severe respiratory failure. However, overall survival all remained high (99.53%; CI 96.72-99.93%), indicating favorable COVID-19.This provides insights into features, therapeutic measures, following large center China. These findings contribute our understanding this population inform strategies mitigate impact pandemic's their care.

Language: Английский

Seroprevalence of SARS-CoV-2 IgG antibodies in children seeking medical care in Seattle, WA June 2020 to December 2022 DOI Creative Commons

Amanda L. Adler,

Alpana Waghmare,

Kirsten Lacombe

et al.

Microbiology Spectrum, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

ABSTRACT Seroprevalence studies play an important role in estimating the number of children infected with SARS-CoV-2. We report SARS-CoV-2 seroprevalence seeking medical care for any reason at a free-standing pediatric hospital Seattle, WA over 2.5-year period and four distinct pandemic waves. randomly selected residual serum samples from young adults as inpatients outpatients Seattle Children’s Hospital between June 2020 December 2022 to test presence anti-nucleocapsid (N) antibodies. Samples were categorized into waves based on Washington State epidemiology: Wave 1 (June 2020–October 2020), 2 (November 2020–June 2021), 3 (July 2021–November 4 (December 2021–December 2022). Patient characteristics COVID-19 vaccine status obtained, zip codes used ascertain Social Vulnerability Index (SVI). Multivariable Poisson regression models robust variance estimates examine relationship patient anti-N-positivity each wave. Among 8,040 7,102 patients included analyses, rose 2.4% (95% CI, 2.0%–3.1%) 25.5% CI 23.3%–27.8%) (following Omicron surge). High SVI, Hispanic ethnicity, or use government insurance was associated increased anti-N positivity most observed steady increase followed by sharp after surge early 2022. Our data demonstrate burden specific groups health disparities within our region throughout pandemic. IMPORTANCE results highlight importance seropositivity essential tools provide information incidence prevalence seropositivity. also reinforce other reports demonstrating inequitable that this continued persist pandemic, even high adherence mitigation efforts. It highlights SVI’s value identifying communities must be part research, public vaccination strategies.

Language: Английский

Citations

1
Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study DOI Creative Commons
Douglas D. Fraser, Devika Singh,

Ester Cela

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 4, 2025

Language: Английский

Citations

0
Post–COVID-19 Condition in Children 6 and 12 Months After Infection DOI Creative Commons
Frederick Dun-Dery, Jianling Xie,

Kathleen Winston

et al.

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(12), P. e2349613 - e2349613

Published: Dec. 28, 2023

There is a need to understand the long-term outcomes among children infected with SARS-CoV-2.

Language: Английский

Citations

6
COVID-19 vaccine confidence, concerns, and uptake in children aged 5 and older in Calgary, Alberta: a longitudinal cohort study DOI Creative Commons
Emily J. Doucette, Leah J. Ricketson, Tarannum Tarannum

et al.

Paediatrics & Child Health, Journal Year: 2023, Volume and Issue: 29(3), P. 150 - 157

Published: Sept. 19, 2023

Beginning early in the pandemic, there was a worldwide effort to develop effective vaccines against SARS-CoV-2 virus. Before and after approval implementation of vaccines, were concerns about their need as well safety rapid development. We explored child demographic characteristics parental identify factors associated with decision vaccinate.

Language: Английский

Citations

2
SARS-CoV-2 seroprevalence among children in Greece during Omicron variant period DOI
Dimitra Dimopoulou,

Despoina Sotiri,

Dimitra Kousi

et al.

European Journal of Pediatrics, Journal Year: 2024, Volume and Issue: 183(5), P. 2491 - 2499

Published: March 13, 2024

Language: Английский

Citations

0
Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years DOI
Anne Tsampalieros, Roger Zemek, Nicholas Barrowman

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(20), P. 125981 - 125981

Published: May 23, 2024

Language: Английский

Citations

0
Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada DOI Creative Commons
Leah J. Ricketson, Emily J. Doucette, Isabella Alatorre

et al.

BMC Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(1)

Published: July 18, 2024

Abstract Background There are few reports of longitudinal serologic responses in children following Sars-CoV-2 infection and vaccination. This study describes SARS-CoV-2 antibody infection, vaccination, or both (hybrid immunity) a cohort Canadian children. The objectives our were to compare levels hybrid immunity examine decline after final antigen exposure. Methods Alberta Childhood COVID-19 Cohort (AB3C) was prospective conducted from July 2020 September 2022 with repeat sampling across 5 visits. Children under 18 years age enrolled for serial measurement virus vaccine infection. Results sample size 919; participants 50.5% female, 48.2% > 12 88.5% white ethnicity. median peak spike IgG level those only not different no vaccination (233 AU/mL (IQR: 99–944 AU/mL) vs. 3 1–5 AU/mL; P = 0.1765). Participants infections had higher than where preceded (median: 36,660 22,084 − 40,000 17,461 10,617 33,212 AU/mL); < 0.0001). In linear mixed methods model, infection-only low that stayed stable over the duration without further exposures. Those slowest rate time at 4% (95%CI: 2-5%) per week, compared 7% 6-8%) week. Conclusions conferred through (2 + doses) followed by highest longest lasting levels, who an vaccination-only, infection-only. longer-term clinical importance these findings, related prevention repeated severe outcomes need doses, is yet known.

Language: Английский

Citations

0
Temporal patterns of asymptomatic SARS‐CoV‐2 infection among pediatric population in Japan: A 3‐year analysis DOI

Kei Kozawa,

Yuki Higashimoto, Yoshiki Kawamura

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(8)

Published: Aug. 1, 2024

To elucidate the seroprevalence and rate of asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Japanese children, serological analysis was performed using serum samples collected from March 2020 to February 2023. A total 1493 were during first study period (March 2021). None positive for SARS-CoV-2 antibody. In second 2021 2022), seven 1055 patients (0.7%) experienced infection. The third 2022 2023) divided into three terms: June 30, 2022; July October November gradually increased throughout this period, rates 6.0%, 18.6%, 30.4% terms, respectively. Pediatric cases occurred after surge Omicron variants. Since none antibody-positive had a previous history disease 2019, may represent

Language: Английский

Citations

0
Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting DOI Creative Commons

Ploy Pattanakitsakul,

Chanya Pongpatipat,

Chavachol Setthaudom

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(9), P. e0310860 - e0310860

Published: Sept. 24, 2024

Globally, cases of children’s coronavirus disease 2019 (COVID-19) have been reported since the pandemic started. Most children an asymptomatic or mild infection. Therefore, incidence rate COVID-19 in might underestimated. This study aimed to determine (1) seroprevalence (and seroconversion rates) COVID-19, including associated risk factors, pediatric patients visiting hospitals; and (2) immunological responses COVID-19. was a prospective, cross-sectional study. Patients aged 0–18 years who visited hospital from September 2020 February 2022 were included. Demographic, clinical, laboratory data reviewed. A total 1,443 enrolled. Of these, 323 (22.6%) had history In pre-Delta period, increased 4.1% 70.6% all included 0.5% 10% without known compared with Delta-Omicron period. The 6.8% (19 per 100 person-years) Risk factors for seropositivity respiratory symptoms, being outpatient department setting, infection during Exposure household members confirmed factor seroconversion. Infection period testing conducted >2 weeks after onset symptoms spike immunoglobulin (Ig) M nucleocapsid IgG, respectively. High IgG levels pneumonia Pediatric exposed should be tested Nucleocapsid can used as surrogate marker identify may experienced screening tool outbreak, regardless vaccination status.

Language: Английский

Citations

0
Surveillance and Outcomes of Pediatric Hematopoietic Stem Cell Transplantation Recipients During the Recent COVID-19 Outbreak in China DOI Creative Commons
Xiaodong Wang, Uet Yu, Chao Ding

et al.

Infection and Drug Resistance, Journal Year: 2023, Volume and Issue: Volume 16, P. 7455 - 7464

Published: Dec. 1, 2023

The COVID-19 pandemic presents challenges for healthcare systems globally, especially in vulnerable populations such as pediatric hematopoietic stem cell transplant (HSCT) recipients. This study examines the clinical characteristics and outcomes of infection HSCT recipients within one year post-HSCT.Retrospective analysis was conducted on data from 247 patients. None them had received SARS-CoV-2 vaccination or prior infection. confirmed using RT-PCR testing. disease severity categorized according to established guidelines. Demographic, clinical, laboratory, imaging treatment were collected.The median age cohort 7±3.7 years, with thalassemia major predominant underlying disease. Allogeneic performed majority cases, haploidentical donors being most common source grafts. Nearly half patients developed COVID-19, significantly higher rates observed over 100 days compared post-HSCT (40.1% vs 21.7%, p<0.05, Fisher's Exact test). Fever (n=107, 43.2%) cough (n=88, 35.6%) symptoms. While mild did not require specific anti-viral treatment, a significant proportion required hospitalization (n=34, 13.8%). Various treatments employed hospitalized patients, including Paxlovid (n=19, 55.9%), methylprednisolone (n=7, 20.6%), IL-6 antibody (n=2, 5.9%), mesenchymal cells (n=3, 8.8%), exosomes nebulization therapy 5.9%). Despite multidisciplinary approaches, patient died severe respiratory failure. However, overall survival all remained high (99.53%; CI 96.72-99.93%), indicating favorable COVID-19.This provides insights into features, therapeutic measures, following large center China. These findings contribute our understanding this population inform strategies mitigate impact pandemic's their care.

Language: Английский

Citations

0